Literature DB >> 16495574

Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge.

Sylvia R Treviño1, Amy R Permenter, Marilyn J England, Narayanan Parthasarathy, Paul H Gibbs, David M Waag, Tran C Chanh.   

Abstract

Glanders is a debilitating disease with no vaccine available. Murine monoclonal antibodies were produced against Burkholderia mallei, the etiologic agent of glanders, and were shown to be effective in passively protecting mice against a lethal aerosol challenge. The antibodies appeared to target lipopolysaccharide. Humoral antibodies may be important for immune protection against B. mallei infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495574      PMCID: PMC1418687          DOI: 10.1128/IAI.74.3.1958-1961.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins.

Authors:  S M Jones; J F Ellis; P Russell; K F Griffin; P C F Oyston
Journal:  J Med Microbiol       Date:  2002-12       Impact factor: 2.472

2.  [The pathomorphology and pathogenesis of glanders in laboratory animals].

Authors:  N R Diadishchev; A A Vorob'ev; S B Zakharov
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  1997 Mar-Apr

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei.

Authors:  L E Bryan; S Wong; D E Woods; D A Dance; W Chaowagul
Journal:  Can J Infect Dis       Date:  1994-07

5.  Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant.

Authors:  D DeShazer; D M Waag; D L Fritz; D E Woods
Journal:  Microb Pathog       Date:  2001-05       Impact factor: 3.738

6.  Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant.

Authors:  S L Reckseidler; D DeShazer; P A Sokol; D E Woods
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

7.  Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice.

Authors:  Kei Amemiya; Gary V Bush; David DeShazer; David M Waag
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

8.  Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei.

Authors:  Daniel Godoy; Gaynor Randle; Andrew J Simpson; David M Aanensen; Tyrone L Pitt; Reimi Kinoshita; Brian G Spratt
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 9.  [Glanders--a potential disease for biological warfare in humans and animals].

Authors:  Ofer Lehavi; Orna Aizenstien; Lior H Katz; Ariel Hourvitz
Journal:  Harefuah       Date:  2002-05

10.  A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells.

Authors:  M L Gefter; D H Margulies; M D Scharff
Journal:  Somatic Cell Genet       Date:  1977-03
View more
  20 in total

1.  Natural history of inhalation melioidosis in rhesus macaques (Macaca mulatta) and African green monkeys (Chlorocebus aethiops).

Authors:  John J Yeager; Paul Facemire; Paul A Dabisch; Camenzind G Robinson; David Nyakiti; Katie Beck; Reese Baker; M Louise M Pitt
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

2.  Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

Review 3.  Antibodies for biodefense.

Authors:  Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

4.  The type IV pilin of Burkholderia mallei is highly immunogenic but fails to protect against lethal aerosol challenge in a murine model.

Authors:  Paula J Fernandes; Qin Guo; David M Waag; Michael S Donnenberg
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

5.  Burkholderia thailandensis oacA mutants facilitate the expression of Burkholderia mallei-like O polysaccharides.

Authors:  Paul J Brett; Mary N Burtnick; Christian Heiss; Parastoo Azadi; David DeShazer; Donald E Woods; Frank C Gherardini
Journal:  Infect Immun       Date:  2010-11-29       Impact factor: 3.441

6.  In Vitro and In Vivo studies of monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei.

Authors:  Shimin Zhang; Shaw-Huey Feng; Bingjie Li; Hyung-Yong Kim; Joe Rodriguez; Shien Tsai; Shyh-Ching Lo
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

Review 7.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Sara K Bondi; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

8.  Distinct human antibody response to the biological warfare agent Burkholderia mallei.

Authors:  John J Varga; Adam Vigil; David DeShazer; David M Waag; Philip Felgner; Joanna B Goldberg
Journal:  Virulence       Date:  2012-10-01       Impact factor: 5.882

Review 9.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

10.  A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei.

Authors:  Anthony E Gregory; Barbara M Judy; Omar Qazi; Carla A Blumentritt; Katherine A Brown; Andrew M Shaw; Alfredo G Torres; Richard W Titball
Journal:  Nanomedicine       Date:  2014-09-03       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.